Systemically measured matrix metalloproteinase (MMP)-9 and its endogenous inhibitor TIMP-1 are important proteins and inflammatory mediators in acute coronary syndrome (ACS) [4] . Santana and Tanus-Santos [5] argued that the sample material may raise technical issues. They refer to earlier publications in which higher MMP-9 and TIMP-1 concentrations are obtained in serum compared to plasma [2] . Within different plasma samples, MMP-9 and TIMP-1 concentrations are higher when EDTA is used as anticoagulant compared to heparin [3] .
In clinical and research use, consistent sample material and processing methods should be used to avoid misinterpretations. It is crucial to use the same sample material and the same processing methods throughout the whole study to maintain the comparability. In our study, we used serum collected and processed similarly in all subjects; thus, the difference between ACS patients and their healthy controls were analysed and used in statistical analysis [4] .
Every sample collection and processing methods have its limitations and challenges; plasma is processed from blood by using anticoagulants, and especially EDTA processing interferes and decreases MMP activity [1] . Different blood fluids may describe the inflammatory and disease status slightly differently; serum concentrations include the free circulating and Bsecretable^MMP-9 and TIMP-1, whereas EDTA plasma contains the EDTA-inhibited concentrations. The MMP-9 and TIMP-1 concentrations of cases and controls should be measured from same sample material collected and processed similarly through study.
Compared to plasma, MMP-9 and TIMP-1 are released to serum due to complement, contact, and platelet activation during the coagulation [1] . These processes are important in haemostasis and thrombosis, and they are also involved in inflammation and innate immune response. The elevated MMP-9 concentrations in serum compared to plasma may describe the inflammatory burden or Breservoir^, i.e. the inflammatory potential. Therefore, serum MMP-9 and TIMP-1 have great potential to become cardiac biomarkers in clinical use.
